1. 15786 POINTS
    Bob VineyardPRO
    Founder, Georgia Medicare Plans, Atlanta,GA
    Krystexxa is a medication used to treat gout and can be effective when other treatments have not produced the desired results.

    FDA approval for Krystexxa was granted in 2010.

    In 2011 Medicare assigned a treatment code to Krystexxa.

    Krystexxa is infusion therapy, covered under Medicare Part B. Due to the cost ($60,000 per year) there may be limits placed on how many treatments will be approved by Medicare.
    Answered on May 8, 2013
  2. Did you find these answers helpful?
    Yes
    No
    Go!

Add Your Answer To This Question

You must be logged in to add your answer.


<< Previous Question
Questions Home
Next Question >>